The International Journal of Neuropsychopharmacology



Letter to the Editor

Successful initiation of clozapine treatment despite morning pseudoneutropenia


David Esposito a1c1, Guy Chouinard a1, Patrick Hardy a1 and Emmanuelle Corruble a1
a1 Department of Psychiatry, Bicêtre Hospital, Assistance Publique – Hôpitaux de Paris, Paris XI University, INSERM U 669, France

Article author query
esposito d   [PubMed][Google Scholar] 
chouinard g   [PubMed][Google Scholar] 
hardy p   [PubMed][Google Scholar] 
corruble e   [PubMed][Google Scholar] 

The dibenzodiazepine derivative clozapine is an atypical antipsychotic that has shown efficacy in schizophrenic patients refractory to other antipsychotic drugs. It has been unique in both symptom resolution and improvement in the quality of life (Pickar, 1995). Because of its known risk to cause agranulocytosis (0.80% at 1 yr, 0.91% at 1.5 yr; Alvir et al., 1993), clozapine is restricted to schizophrenic patients for whom other antipsychotic drugs are ineffective and to those who experience intolerable adverse effects.

(Received June 30 2005)
(Revised July 10 2005)
(Revised July 17 2005)
(Accepted July 21 2005)
(Published Online September 28 2005)


Correspondence:
c1 Department of Psychiatry, Bicêtre Hospital, Assistance Publique – Hôpitaux de Paris, Paris XI University, INSERM U 669, 8 rue du Général Leclerc, 94275 Le Kremlin-Bicêtre Cédex, France. Tel.: +33-1-45212524 Fax: +33-1-45212864 E-mail: david.esposito@club-internet.fr